Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: a regulatory postmarketing surveillance, the …
H Inoue, M Umeyama, T Yamada… - Journal of …, 2019 - Wiley Online Library
Background Apixaban, a non‐vitamin K oral anticoagulant (NOAC), was approved in Japan
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …
[引用][C] Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the …
H Inoue, M Umeyama, T Yamada, H Hashimoto… - Journal of …, 2019 - cir.nii.ac.jp
Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in
clinical practice: A regulatory postmarketing surveillance, the STANDARD study | CiNii …
clinical practice: A regulatory postmarketing surveillance, the STANDARD study | CiNii …
Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the …
H Inoue, M Umeyama, T Yamada… - Journal of …, 2019 - search.proquest.com
Background Apixaban, a non‐vitamin K oral anticoagulant (NOAC), was approved in Japan
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …
[HTML][HTML] Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the …
H Inoue, M Umeyama, T Yamada… - Journal of …, 2019 - ncbi.nlm.nih.gov
Background Apixaban, a non‐vitamin K oral anticoagulant (NOAC), was approved in Japan
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …
Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the …
H Inoue, M Umeyama, T Yamada, H Hashimoto… - Journal of …, 2019 - europepmc.org
Background Apixaban, a non-vitamin K oral anticoagulant (NOAC), was approved in Japan
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …
Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the …
H Inoue, M Umeyama, T Yamada… - Journal of …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Apixaban, a non-vitamin K oral anticoagulant (NOAC), was approved in Japan
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …
Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the …
H Inoue, M Umeyama, T Yamada, H Hashimoto… - Journal of …, 2019 - europepmc.org
Background Apixaban, a non-vitamin K oral anticoagulant (NOAC), was approved in Japan
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …